Primary Graft Dysfunction Clinical Trial
Official title:
Measurement of Extravascular Lung Water to Detect and Predict Primary Graft Dysfunction Following Lung Transplant
Primary graft dysfunction (PGD) is the most common cause of early morbidity and mortality
following lung transplant and is characterized by acute lung injury and capillary leak
leading to an increase in extravascular lung water index (ELWI) and impaired graft function.
PGD has many features in common with acute respiratory distress syndrome (ARDS). PGD may be
life-threatening and can also lead to impaired long term lung function. In ARDS, a
restrictive fluid strategy has been associated with an improvement in lung function and
outcomes. Accurate methods of evaluating, quantifying and guiding the hemodynamic / fluid
management and limiting the extent of ELWI that accumulates in the setting of PGD are
lacking. Using transpulmonary thermodilution to estimate ELWI and the pulmonary permeability
index (PPI) represents a novel approach to fluid management, which has been used in patients
with ARDS, but to date not in the transplant setting. To determine if these measurements may
better guide the management of lung transplant patients, the investigators first wish to
establish whether these methods are able to predict the onset of clinical pulmonary edema
earlier, whether they correlated with traditional markers of PGD, and whether they may be
useful for predicting outcomes.
AIM 1: The investigators will evaluate the correlation between ELWI and current surrogates of
pulmonary edema in lung transplant patients with and without Primary Graft Dysfunction (PGD)
AIM 2: The investigators will correlate the use of ELWI and PPI to determine the presence and
severity of PGD.
AIM 3: a) The investigators will determine whether early measurements of ELWI and PPI can
predict the onset of PGD.
b) Across different strata of PGD, the investigators will determine whether ELWI and PPI have
a differential effect on duration of mechanical ventilation.
The results of the study will be used for the following:
1. Provide the rationale for routine monitoring of ELWI to detect PGD if found to be more
discriminatory and have a stronger association with outcome compared to the current gold
standard.
2. Provide the means of early identification of those as risk of developing PGD in order to
guide management decisions or future therapeutic interventions aimed at preventing or
treating PGD.
3. Provide the requisite groundwork for a clinical trial comparing the effects of an
ELWI-driven protocol versus usual care on ICU outcomes in lung transplant recipients.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05375149 -
Exhaled Breath Particles in Lung Transplantation
|
||
Terminated |
NCT04558333 -
CLAD: Finding Biomarkers to Predict Rejection and/ or Outcome After Lung Transplantation
|
||
Terminated |
NCT01715883 -
Sodium Nitrite in Lung Transplant Patients to Minimize the Risk of Pulmonary Graft Dysfunction
|
Phase 2 | |
Recruiting |
NCT01151826 -
Quantifying Physical and Biochemical Factors That Contribute to Primary Graft Dysfunction After Lung Transplantation
|
N/A | |
Recruiting |
NCT05691205 -
Identifying Optimal PEEP After Lung Transplantation
|
N/A | |
Completed |
NCT02032069 -
Pneumoproteins Expression in the Organ Donor
|
N/A | |
Completed |
NCT01967953 -
Ex-Vivo Lung Perfusion to Increase the Number of Organs for Transplantation
|
Phase 1 | |
Recruiting |
NCT00506532 -
The Use of Surfactant in Lung Transplantation: A Randomized Control Pilot Study
|
Phase 2/Phase 3 | |
Completed |
NCT06159933 -
Primary Graft Dysfunction, Pronation, Bilateral Lung Transplants
|
N/A | |
Recruiting |
NCT03156894 -
Heart Transplant and Primary Transplant Dysfunction: a Retrospective Analysis of the Strasbourg Experience
|
N/A | |
Recruiting |
NCT00457847 -
Identifying Genetic Characteristics That Increase Risk of Primary Graft Dysfunction Following Lung Transplantation
|
||
Recruiting |
NCT00552357 -
Risk Factors That Increase the Chance of Developing Primary Graft Dysfunction After Lung Transplantation
|
||
Withdrawn |
NCT04505878 -
Perioperative Vitamin C Lung Transplant
|
Phase 2 |